

## Lilly to Participate in Guggenheim Healthcare Talks Idea Forum

February 7, 2020

INDIANAPOLIS, Feb. 7, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 13, 2020. Jacob Van Naarden, chief operating officer for Loxo Oncology at Lilly; Eric Dozier, vice president, Lilly Oncology North America; and Maura Dickler, M.D., vice president, oncology late phase development, will participate in a fireside chat at 1:00 p.m., Eastern Time.

A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at <a href="https://investor.lilly.com/webcasts-and-presentations">https://investor.lilly.com/webcasts-and-presentations</a>. A replay of the presentation will be available on this same website for approximately 90 days.

## **About Eli Lilly and Company**

Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at <a href="https://www.lilly.com">www.lilly.com</a>. F-LLY

Refer to: Mark Taylor; <a href="mark.taylor@lilly.com">mark.taylor@lilly.com</a>; (317) 276-5795 (Media) Kevin Hern; <a href="mark.taylor@lilly.com">hern kevin r@lilly.com</a>; (317) 277-1838 (Investors)



Usew original content to download multimedia: <a href="http://www.prnewswire.com/news-releases/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum-301001069.html">http://www.prnewswire.com/news-releases/lilly-to-participate-in-guggenheim-healthcare-talks-idea-forum-301001069.html</a>

SOURCE Eli Lilly and Company